## ILMN: Illumina, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($123.26)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. United States DNA Sequencing Market 2031 | Growth Drivers, Key Players & Investment Opportunities | Leading Companies - Bio-Rad Laboratories Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche, Illumina Inc.**
- Source: openPR.com | 20251215T120923 | Bullish | Relevance: 100%
- The United States DNA Sequencing Market is expected to grow at a CAGR of 11.3% during the forecast period (2024-2031). Recent developments include Illumina's collaboration with MyOme and acquisition of SomaLogic, and Pacific Biosciences' updates to its Revio sequencing system, all aimed at advancing genomic applications and personalized medicine. Key market players include Illumina Inc., Danaher Corporation, and Thermo Fisher Scientific Inc., with North America holding the largest market share due to its advanced healthcare infrastructure and genomics research funding.

**2. Nikko Asset Management Americas Inc. Increases Stake in Illumina, Inc. $ILMN**
- Source: MarketBeat | 20251214T110910 | Somewhat-Bullish | Relevance: 100%
- Nikko Asset Management Americas Inc. significantly increased its stake in Illumina, Inc. ($ILMN) by 28.8% in Q2, bringing its total holdings to 867,981 shares valued at approximately $82.8 million. Other institutional investors also raised their positions, leading to an overall institutional ownership of 89.42%. Despite a "Hold" consensus rating from Wall Street and an average price target of $115, Illumina exceeded its latest quarterly EPS and revenue estimates and provided positive FY2025 guidance.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $110 | $100 | +10% |
| 2025-12-15 | JP Morgan | $130 | $105 | +24% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Underweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.09M) |
| Sells | 10 ($80.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Capital World Invest: 13.1% (+20.0%)
- Blackrock Inc.: 12.2% (-3.5%)
- Vanguard Group Inc: 9.6% (-3.5%)
- State Street Corpora: 3.9% (+6.8%)
- Sessa Capital IM, L.: 3.1% (-0.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.9% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $80M sold (10 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 26.3x stretched relative to 6% growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (2 raises, avg +17%). Insider selling cluster ($80.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.2B |
| Beta | 1.44 |
| 52W Range | $68.70 - $153.06 |
| Short Interest | 7.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 26.3 |
| Current P/E | 27.9 |
| YoY Growth | 6.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.2% to 1.2% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.8pp (needs >3.0% for momentum thesis). MRS_5 (-1.3%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.24% (CS: 53) | Neutral |
| RSI_14 | 60.4 | Neutral |
| MACD Histogram | -0.30 | Bearish |
| vs SMA20 | 1.022x | Above |
| vs SMA50 | 1.140x | Above |
| vs SMA200 | 1.367x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $131.56
- **Stop Loss:** $123.26 (6.3% risk)
- **Target:** $139.86 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 120
- **Position Value:** $15,787.20
- **Portfolio %:** 15.79%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-05 (Est: $1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.34 | +14.7% |
| 2025Q2 | $1.01 | $1.19 | +17.7% |
| 2025Q1 | $0.94 | $0.97 | +3.3% |
| 2024Q4 | $0.92 | $0.86 | -6.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*